BlackRock Fund Advisors’s Astria Therapeutics ATXS Stock Holding History

BlackRock Fund Advisors’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$65K	Buy	302 +12	+4%	+$2.94K	﹤0.01%	3704
2016 Q3	$107K	Hold	290	–	–	﹤0.01%	3608
2016 Q2	$64K	Sell	290 -1,622	-85%	-$489K	﹤0.01%	3773
2016 Q1	$578K	Sell	1,912 -104	-5%	-$35.8K	﹤0.01%	3224
2015 Q4	$959K	Buy	2,016 +229	+13%	+$110K	﹤0.01%	3235
2015 Q3	$867K	Buy	+1,787	New	+$1.28M	﹤0.01%	3210

Other funds holding ATXS

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock Fund Advisors's ATXS Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Astria Therapeutics (ATXS) stake by 4.1% in Q4 2016, buying an estimated $2.94K and bringing the position to 302 shares worth $65K. The position accounts for ﹤0.01% of the portfolio, ranked #3704.

BlackRock Fund Advisors first reported a position in ATXS in Q3 2015 and has held it in 6 quarters since. The position peaked at $959K in Q4 2015. 26 funds tracked by Wall St. Rank hold ATXS as of Q4 2016.

BlackRock Fund Advisors held 302 shares of Astria Therapeutics worth $65K as of Q4 2016.
BlackRock Fund Advisors bought 12 Astria Therapeutics shares in Q4 2016, an estimated $2.94K.
Astria Therapeutics made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #3704 holding.
BlackRock Fund Advisors first reported a position in Astria Therapeutics in Q3 2015 and has held it in 6 quarters since.
BlackRock Fund Advisors's Astria Therapeutics position peaked at $959K in Q4 2015.
26 funds tracked by Wall St. Rank held Astria Therapeutics as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.